Press Release Details

The Quest Diagnostics Health Trends(TM) Report "H1N1 Testing in America: End of the Second Wave?" also indicates that the virus is still the dominant influenza virus in the U.S. and that close to four in ten school-age children tested as recently as last week were infected with the pandemic virus.

"Our data are a welcome indication that H1N1 may not be the health threat during the holidays that it has been throughout the fall," said Jay M. Lieberman, M.D., medical director, infectious diseases, Quest Diagnostics. "Nonetheless, this is no time for people to be complacent about protecting themselves and their families from H1N1 infection. The 2009 H1N1 influenza virus continues to be far and away the most significant source of influenza in every region of the U.S., according to our data. Many millions of people remain susceptible to the virus, which continues to cause serious disease in some individuals.

"In addition, the prospect of a third wave of virus activity next year means it is far too soon to declare victory over H1N1," continued Dr. Lieberman.

Quest Diagnostics analyzed results of nearly 170,000 de-identified patient specimens it tested for the 2009 H1N1 influenza virus in the U.S. between May 11, 2009, when the company introduced its first test for detecting the pandemic virus, and December 9, 2009. Quest Diagnostics is the only company in the U.S. that both performs testing for H1N1 and also provides 2009 H1N1 laboratory testing kits, developed by its Focus Diagnostics business, that are FDA authorized for emergency use by qualified molecular laboratories. The tests employ real-time reverse transcription polymerase chain reaction to qualitatively detect the virus' RNA in a patient's nasal or nasopharyngeal specimens.

Influenza viruses often circulate in waves of activity. The report indicates that two major waves of H1N1 influenza virus activity have affected the U.S., based on the company's test data. The first wave started in early May, following the discovery of the virus in the U.S. in late April. A second wave began in late August and peaked the week ending October 28. Between the weeks ending October 28 and December 9, testing rates fell by 75 percent, and now are roughly equivalent with testing rates experienced when the second wave began.

Other key findings:

    --  The number of specimens that tested positive for 2009 H1N1 influenza has
        declined in all age groups since late October. Children ages five to 14
        continue to experience the highest percentage of H1N1 positive test
        results compared to negative results, with a positivity rate of close to
        40 percent.  "Our findings suggest that children continue to be most
        vulnerable to the H1N1 virus," said Dr. Lieberman.
    --  Nearly every region experienced declines of 60 percent or more in
        positive test results during the two weeks ending December 9 compared to
        the two weeks ending November 25. The most striking decline in positive
        test results occurred in the region comprised by Pennsylvania, Maryland,
        Delaware, Virginia and West Virginia, and the District of Columbia (87
        percent decline).
    --  The 2009 H1N1 influenza virus remains the predominant cause of influenza
        in the U.S., as more than 98 percent of positive influenza A specimens
        are positive for 2009 H1N1 influenza. "Our data provide no evidence that
        seasonal influenza viruses have begun to circulate," added Dr.
        Lieberman.

The Quest Diagnostics investigators believe the decline in testing demand is due to several factors, primarily lower rates of infection due to millions of Americans having already been infected with this influenza virus and the impact of H1N1 vaccines, both of which have reduced the number of people susceptible to infection, and changes in physician test-ordering practices.

To read the full report, please visit QuestDiagnostics.com/HealthTrends.

Quest Diagnostics offers free 2009 H1N1 influenza virus testing services to pregnant woman who are not insured. According to the CDC, infection with the H1N1 virus increases health risks for pregnant woman. For more information, visit www.QuestDiagnostics.com/2009H1N1.

For more information about Quest Diagnostics and influenza testing options, please visit www.QuestDiagnostics.com/2009H1N1 or www.FocusDx.com/2009H1N1.

About the FDA's Emergency Use Authorization

The Focus Diagnostics 2009 H1N1 influenza virus tests have not been FDA cleared or approved. These tests have been authorized by FDA under an Emergency Use Authorization (EUA). These H1N1 tests are only authorized for the duration of the declaration of emergency under section 564(b)(1) of the Act, 21 U.S.C. Section 360bbb-3(b)(1). The declaration of emergency will expire on April 26, 2010, unless it is terminated or revoked sooner or renewed.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at http://www.questdiagnostics.com/.

Contacts:

Wendy Bost

(Media): 973-520-2800

Kathleen Valentine

(Investors): 973-520-2900

SOURCE Quest Diagnostics

http://www.QuestDiagnostics.com